17 Alpha-hydroxyprogesterone Caproate (17P) for Prevention of Preterm Delivery

The drug 17 alpha-hydroxyprogesterone caproate (17P) is an injectable long-acting synthetic derivative of progesterone, administered for the prevention of preterm delivery in patients with a documented history of previous spontaneous preterm birth. 17P must be prepared by, and purchased from, a pharmacy with the ability to compound drugs.

This drug is covered under the Medicaid program as a physician-administered drug only, and is not included in the Medicaid formulary file. Therefore, **Medicaid managed care and Family Health Plus (FHPlus) plans are responsible for covering this medication for their enrollees.** When administered to an enrollee of a managed care plan, reimbursement and documentation requirements are determined by the provider’s contract with the managed care plan.

17P is billed by private physicians, nurse practitioners, nurse midwives and ordered ambulatory providers using procedure code **J3490 Unclassified drugs.** 17P is not included in the Article 28 clinic APG. Under the Medicaid fee-for-service program, reimbursement is “By Report” and the billing provider must submit a paper claim accompanied by an invoice showing the cost of purchase from the compounding pharmacy and NDCs used in compounding, and a report documenting medical need. To identify the drug for rebate purposes, the claim must include the NDC for the bulk powder used in compounding. For more information on billing physician administered drugs, please refer to the [December 2008 Medicaid Update](#).

Effective January 1, 2011, rebate agreements with all manufacturers of bulk powders used to formulate the 17P compound will expire. The NYS Medicaid program, and Medicaid managed care and FHPlus plans, will continue to cover 17P. A future communication will be published instructing Medicaid fee-for-service providers on new eMedNY billing procedures.

Questions? Contact Bureau of Program Planning & Implementation at: (518) 473-0122.

October 2010